Mark C. McKenna is Chairman & President at Prometheus Biosciences, Inc. (RXDX). They have made 2 open-market trades across 2 companies since 2019, most recently 2026-01-07.
CIK 0001749623
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $991K since 2024, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APGE | BUY | 2024-12-12 | 2024-12-16 | $49.54 | $991K | -2.3% | -13.7% | -13.9% |
| RXDX | SELL · 10b5-1 | 2023-03-15 | 2023-03-17 | $116.14 | $2.9M | -1.1% | +72.0% | +77.7% |
| RXDX | SELL · 10b5-1 | 2023-03-01 | 2023-03-03 | $125.14 | $1.4M | -8.3% | -13.1% | +57.5% |
| RXDX | SELL · 10b5-1 | 2023-02-15 | 2023-02-17 | $120.82 | $7.7M | +1.0% | -5.8% | +58.2% |
| RXDX | SELL · 10b5-1 | 2023-01-17 | 2023-01-19 | $118.99 | $3.0M | -4.6% | +1.3% | +62.8% |
| BHC | SELL | 2019-08-19 | 2019-08-21 | $21.83 | $470K | -4.0% | +1.8% | +25.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.